The iLet Experience Study
← catalyst calendarNCT06891898 · readout ≤ 315 d
Sponsored by Beta Bionics, Inc. (industry) · BBNX — their whole pipeline →. With The Scripps Research Institute.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,875estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-01 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes
Intervention
- Device: iLet Dosing Decision Software — also filed as iLet Bionic Pancreas
Primary outcome
what the primary-completion date above is the date OFSevere Hypoglycemia/cognitive impairment
measured 1 year
Permalink · BBNX's whole pipeline · Catalyst calendar · Every registered study · What changed